Scancell to provide update on SCIB1 data in resected melanoma patients at 2015 ASCO Annual Meeting
Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, today announces that the latest data from the ongoing Phase 1/2 clinical trial of SCIB1, its DNA ImmunoBody® being developed for the treatment of patients with melanoma, will be presented in a poster at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 29 - June 2, 2015.
An abstract of the poster can be accessed through the ASCO website at: http://abstracts.asco.org/. The summary of the results contained therein relates to data available at the time of abstract submission. A further update on clinical outcomes, including survival time, will be given as part of the poster presentation.
SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. The trial is an open label, non-randomised study to determine the safety and tolerability of SCIB1 administered intramuscularly using an electroporation device (TDS-IM, manufactured by Ichor Medical Systems, USA). The study is also assessing immune response and anti-tumour activity, and the ability of SCIB1 to delay or prevent disease recurrence in patients with resected disease.
The title, timing and location of the poster presentation is as follows:
Title: An adjuvant clinical trial of SCIB1, a DNA vaccine that targets dendritic cells in vivo, in fully resected melanoma patients
Presenter: Prof Poulam M. Patel, MD, PhD
Session: Melanoma/Skin Cancers
Day/Date: Monday 1 June, 2015
Session Time: 1:15 PM - 4:45 PM
Location: S Hall A
For Further Information:
Dr Richard Goodfellow, Joint CEO Scancell Holdings Plc + 44 (0) 20 3727 1000
Professor Lindy Durrant, Joint CEO Scancell Holdings Plc
Robert Naylor/Maisie Atkinson Panmure Gordon + 44 (0) 20 7886 2500
Mo Noonan/Simon Conway FTI Consulting + 44 (0) 20 3727 1000
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.
Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial. Data from the trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects. In patients with resected disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence.
Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system where inflammation is stimulated at the tumour site and the cytotoxic Tlymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
Pre-clinical data on a combination of SCIB1 or SCIB2 and checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune checkpoint pathways) have shown enhanced tumour destruction and significantly longer survival times than when either treatment was used alone.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.
After buying 77.56mln new shares at a price of 5p per share, which was a slight discount to the 5.35p closing price the previous day, the Vulpes Life Sciences Fund will have a 16.67% stake in the company.
Fri, 21 Jun 2019 08:21:00
Scancell Holdings PLC (LON:SCLP) CEO Cliff Holloway caught up with Proactive London's Andrew Scott following the announcement they'd raised £3.88mln via a placing with a single new investor to help fund the progression of its lead cancer asset into clinical trials.
The Vulpes Life Sciences Fund will now have a 16.67% stake in the company when the shares are issued next Monday.
Thu, 13 Jun 2019 09:53:00
“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”
Thu, 13 Jun 2019 06:31:00
Sign up to our newsletter to stay up to date with Scancell